S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:GOSS

Gossamer Bio (GOSS) Stock Price, News & Analysis

$1.18
+0.01 (+0.85%)
(As of 03/28/2024 ET)
Today's Range
$1.15
$1.22
50-Day Range
$0.80
$1.51
52-Week Range
$0.45
$1.88
Volume
1.07 million shs
Average Volume
1.10 million shs
Market Capitalization
$266.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.05

Gossamer Bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
582.2% Upside
$8.05 Price Target
Short Interest
Healthy
4.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.38mentions of Gossamer Bio in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$39,682 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.72) to ($0.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.30 out of 5 stars

Medical Sector

159th out of 938 stocks

Pharmaceutical Preparations Industry

63rd out of 417 stocks

GOSS stock logo

About Gossamer Bio Stock (NASDAQ:GOSS)

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

GOSS Stock Price History

GOSS Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
GOSS Apr 2024 1.500 put
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
GOSS Apr 2024 1.000 put
Barclays Keeps Their Hold Rating on Gossamer Bio (GOSS)
Gossamer Bio Posts Narrower Loss In Q4 - Quick Facts
Gossamer Bio Inc (GOSS)
7 Micro-Cap Stocks That Could Majorly Surprise Investors
Gossamer Bio Inc.
5 Small-Cap Stocks with High Potential
See More Headlines
Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GOSS
Fax
N/A
Employees
135
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.05
High Stock Price Target
$15.00
Low Stock Price Target
$1.25
Potential Upside/Downside
+582.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-179,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.28 per share

Miscellaneous

Free Float
204,152,000
Market Cap
$266.18 million
Optionable
Optionable
Beta
1.73
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Faheem Hasnain (Age 66)
    Co-Founder, CEO, President & Chairman
    Comp: $902.52k
  • Mr. Bryan  GiraudoMr. Bryan Giraudo (Age 49)
    COO & CFO
    Comp: $690.59k
  • Dr. Richard Aranda M.D. (Age 63)
    Chief Medical Officer
    Comp: $625.24k
  • Mr. Christian Waage (Age 57)
    Executive Vice President of Technical Operations & Administration
    Comp: $583.16k
  • Mr. Jeff Boerneke
    General Counsel & Secretary
  • Ms. Deanna Weber
    Senior Vice President of Human Resources
  • Mr. Mario Orlando
    Senior Vice President of Commercial New Product Planning
  • Ms. Caryn L. Peterson (Age 65)
    Executive Vice President of Regulatory Affairs
  • Mr. Matt Cravets
    Senior Vice President of Biometrics
  • Dr. Lisa Elizabeth Nolan Ph.D. (Age 62)
    MD & President of Gossamer Bio Ireland

GOSS Stock Analysis - Frequently Asked Questions

Should I buy or sell Gossamer Bio stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GOSS shares.
View GOSS analyst ratings
or view top-rated stocks.

What is Gossamer Bio's stock price target for 2024?

5 Wall Street analysts have issued 1 year price objectives for Gossamer Bio's shares. Their GOSS share price targets range from $1.25 to $15.00. On average, they expect the company's share price to reach $8.05 in the next year. This suggests a possible upside of 582.2% from the stock's current price.
View analysts price targets for GOSS
or view top-rated stocks among Wall Street analysts.

How have GOSS shares performed in 2024?

Gossamer Bio's stock was trading at $0.9125 at the start of the year. Since then, GOSS shares have increased by 29.3% and is now trading at $1.18.
View the best growth stocks for 2024 here
.

Are investors shorting Gossamer Bio?

Gossamer Bio saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 11,090,000 shares, a drop of 22.4% from the February 29th total of 14,300,000 shares. Based on an average daily trading volume, of 1,080,000 shares, the short-interest ratio is currently 10.3 days.
View Gossamer Bio's Short Interest
.

When is Gossamer Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our GOSS earnings forecast
.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) announced its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21).

What other stocks do shareholders of Gossamer Bio own?
When did Gossamer Bio IPO?

Gossamer Bio (GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.16%), Vanguard Group Inc. (5.16%), Octagon Capital Advisors LP (4.08%), Platinum Investment Management Ltd. (3.09%), Palo Alto Investors LP (2.64%) and Madison Avenue Partners LP (2.24%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Richard Aranda and Waage Christian.
View institutional ownership trends
.

How do I buy shares of Gossamer Bio?

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GOSS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners